Clinical trials: Marburg Virus Disease
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Marburg Virus Disease
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
- Trial name
- NCT03800173
- Testing
- galidesivir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Marburg Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01566877
- Testing
- AVI-7288
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Marburg Virus Disease
Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects
This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP [Angola] (PHV01, Marburg Virus glycoprotein [MARV GP] Vaccine) in healthy adults.
- Trial name
- PHV01 (NCT06265012)
- Testing
- PHV01
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC